In the BioHarmony Drug Report Database

"Preview" Icon

Evolocumab

Repatha (evolocumab) is an antibody pharmaceutical. Evolocumab was first approved as Repatha on 2015-07-17. It is used to treat atherosclerosis and hypercholesterolemia in the USA. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia. The pharmaceutical is active against proprotein convertase subtilisin/kexin type 9.

 

Trade Name

 

Repatha
 

Common Name

 

evolocumab
 

ChEMBL ID

 

CHEMBL2364655
 

Indication

 

atherosclerosis, dyslipidemias, hypercholesterolemia
 

Drug Class

 

Monoclonal antibodies: fully human, cardiovascular indications

Image (chem structure or protein)

Evolocumab structure rendering